WRF Capital
WRF Capital is the venture investment arm of the Washington Research Foundation, deploying roughly $5M annually into early-stage startups spun out of Washington state research institutions across life sciences, enabling technologies, and AI. It operates an integrated model combining venture investing with phased commercialization grants, postdoctoral fellowships, and large-scale BioInnovation initiatives.
- Company typePrivate
- Founded1981
- HeadquartersSeattle, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What WRF Capital does
WRF Capital is the dedicated venture investment vehicle of the Washington Research Foundation (WRF), a private, independent nonprofit foundation established in 1981 by Tom Cable, Bill Gates Sr., and Hunter Simpson to operationalize the Bayh-Dole Act for Washington state's research institutions. WRF Capital invests approximately $5 million per year in early-stage startups spun out of the University of Washington, Washington State University, Fred Hutchinson Cancer Research Center, the Institute for Systems Biology, Seattle Children's Research Institute, the Allen Institute for AI, and other Washington state nonprofit research institutions, often leading or syndicating the first institutional round. The portfolio spans life sciences (biotechnology, pharmaceuticals, medical devices, digital health) and enabling technologies (advanced materials, scientific instrumentation, AI), and includes companies such as Sana Biotechnology (valued at $6B+ shortly after its 2021 IPO), A-Alpha Bio, Outpace Bio, Monod Bio, Xaira Therapeutics, and mpathic.
The organization's broader operating model extends well beyond pure venture investing into an integrated stack of grant and talent programs. WRF administers phased Technology Commercialization Grants (up to $1M in direct costs across three phases), three-year Postdoctoral Fellowships, Student Programs at Washington colleges and universities, and large-scale BioInnovation Grants — most recently committing $32M+ to four flagship initiatives including the Seattle Hub for Synthetic Biology. Since 1993, WRF has disbursed more than $190 million in grants, and its licensing program has returned more than $445 million to research institutions including the University of Washington, anchored by landmark patents such as the yeast expression technology licensed to Genentech that underpins manufacturing of insulin and Merck's Gardasil vaccine.
WRF Capital is supported by a 12-person team led by President & CEO Orin Levine, Ph.D. (former Gates Foundation senior director and Johns Hopkins professor) and CFO Morgan Hellar, with senior investment professionals holding cross-disciplinary credentials in AI/ML, bioengineering, and health economics. The foundation is self-funded through an endowment generated by its licensing program and reinvested into both grants and venture investments; it has no external LPs or parent company, and operates from a Seattle headquarters that includes a 15,000-square-foot WRF Venture Center subleased to portfolio companies. The combination of patient, endowment-derived capital, multi-decade institutional relationships, and an integrated grant-plus-venture model positions WRF Capital as a structurally unique "first money in" investor in Washington state's research-driven startup pipeline.
WRF Capital firmographics
Firmographics- Name
- WRF Capital
- Legal name
- Washington Research Foundation
- Website
- https://wrfseattle.org
- Company type
- Private
- Founded year
- 1981
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- WRF Capital is the venture investment arm of the Washington Research Foundation, deploying roughly $5M annually into early-stage startups spun out of Washington state research institutions across life sciences, enabling technologies, and AI. It operates an integrated model combining venture investing with phased commercialization grants, postdoctoral fellowships, and large-scale BioInnovation initiatives.
- Ownership category
- akta.pro rank
WRF Capital industry classification
Industry- Product category
- Venture Capital and Research Foundation Grant Programs
- NAICS
- Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
Keywords
Where WRF Capital is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
WRF Capital business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others, Marketing or Sales
Revenue model
- Investment Returns (Portfolio Exit): WRF Capital generates returns through successful portfolio company exits including IPOs and acquisitions. These returns are reinvested into additional local startups and to support grantmaking activities.
- Licensing Revenue: WRF earned more than $445 million for the University of Washington and other nonprofit research institutions through its licensing program, returning proceeds to originating institutions to fund additional research and scholarship.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Technology Commercialization Grant - Phase 1 |
| Other | Multi-year contract | Technology Commercialization Grant - Phase 2 |
| Other | Multi-year contract | Technology Commercialization Grant - Phase 3 |
| Subscription | Annual | Postdoctoral Fellowship |
| Other | Annual | Student Program Funding |
| Other | Pay-as-you-go | Startup Investment |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
WRF Capital product offering
Product offeringCore offering
WRF Capital is the early-stage venture capital investment vehicle of Washington Research Foundation, investing approximately $5 million annually in Washington state startup companies spun out from nonprofit research institutions. The foundation complements these investments with technology commercialization grants, postdoctoral fellowships, student program funding, and large-scale BioInnovation Grants to bridge the gap between discovery research and commercial investment in life sciences and enabling technologies.
Product overview
WRF Capital is the investment vehicle for Washington Research Foundation, a private foundation supporting groundbreaking research and early-stage companies in Washington state since 1981. The organization operates through its core WRF Capital Investment Program for venture investments in startups, complemented by grant programs including Technology Commercialization Grants, WRF Postdoctoral Fellowships, Student Programs, and BioInnovation Grants. Together these programs support the development of innovations in life sciences and enabling technologies from Washington state research institutions. The organization has invested in more than 130 local startups since 1996, earned over $445 million for research institutions through licensing, and provided over $190 million in grants.
Differentiator
Problem solved
Functional benefit
Products and services
- WRF Capital Investment Program Early-stage venture capital investments in startup companies based in Washington state, with a focus on spinouts from nonprofit research institutions including UW, WSU, Fred Hutch, ISB, and Seattle Children's. The program invests approximately $5 million annually.
- Technology Commercialization Grants Project-based funding supporting the commercial development of technology-based products from Washington state research institutions, with phased funding up to $1 million through pre-proposal, Phase 1 ($10K-$100K), Phase 2 (up to $250K), and Phase 3 (up to $1M) stages.
- WRF Postdoctoral Fellowships Three-year salary support for outstanding postdoctoral scientists conducting innovative, translational research at Washington state research institutions, including $15,000 for research supplies, equipment, and/or travel.
- Student Programs Funding for student programs at Washington state colleges and universities related to STEM research and entrepreneurship, including undergraduate research fellowships, ARCS graduate scholars, and innovation training fellowships.
- BioInnovation Grants Large-scale strategic funding for emergent opportunities to advance Washington state's life sciences ecosystem, including support for Seattle Hub for Synthetic Biology, WSU's Soil to Society initiative, Fred Hutch-Seattle Children's Bridging the Clinical Gap collaboration, and UW Institute for Protein Design's De Novo Design of Catalytic Enzymes initiative.
- WRF Venture Analyst Program Part-time opportunity for graduate students and postdoctoral fellows to conduct due diligence on grant and investment opportunities in life sciences and enabling technologies, working up to 10 hours per week at $35/hour.
Quantifiable outcome
- 130+ startups funded since 1996 with successful exits including IPOs and acquisitions
- +3 more outcomes
Companies that use WRF Capital
Customer profileNamed customers10 records
Segments2 records
Ideal customer profiles4 records
WRF Capital technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
WRF Capital partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core, major, minor and flagship.
- University of WashingtoncorePrimary source of technology spinouts; UW is the largest nonprofit research institution in Washington state with leading programs in life sciences, engineering, and technology.
- Washington State UniversitycoreMajor research university in Washington state and source of technology spinouts; WRF supports WSU commercialization gap fund and collaborative programs.
- Fred Hutchinson Cancer Research CentercoreLeading cancer research center in Seattle; source of numerous biotech spinouts; WRF supports Bridging the Clinical Gap collaboration and IND-Enabling programs.
- Seattle Children's Research InstitutecoreSource of pediatric healthcare and biotech innovations; WRF provided $12.5M to Invent at Seattle Children's Postdoctoral Scholars Program.
- Institute for Systems Biology (ISB)corePioneering systems biology research institute; source of biotech spinouts; WRF supports ISB Innovator Award Program.
- Allen Institute for AIcoreAI research institute; source of AI-focused technology spinouts including Birch.AI.
- Creative Destruction Lab (CDL-Seattle)majorGlobal startup program for seed-stage, science-based companies located at UW Foster School of Business; benefits from partnerships with Microsoft, WRF, The Foster Foundation, and Allen Institute for AI.
- MicrosoftminorCorporate partner supporting Creative Destruction Lab-Seattle; represents industry collaboration with academic ecosystem.
- Seattle Hub for Synthetic Biologyflagship$32+ million pledged through BioInnovation Grants; SeaBridge fellowship program; major initiative to advance cell and genome technologies in Washington state.
- ARCS Foundation Seattle ChapterminorAdvancing science in America by funding PhD fellowships for outstanding STEM scholars at UW and WSU; WRF provides annual sponsorship.
- Benaroya Research InstitutecoreAutoimmune disease research institute; source of biotech innovations; recipient of WRF Postdoctoral Fellowship and technology commercialization grants.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
WRF Capital competitors and assessment
Company assessmentDirect peers
- ARCH Venture Partners: ARCH is a long-running early-stage venture firm that builds and invests in life sciences and technology companies, frequently out of academic research institutions. Like WRF Capital, ARCH is often the first capital into deep-tech spinouts, making it the closest direct comparability for WRF's research-spinout investment model.
- Madrona Venture Group: Madrona is the Pacific Northwest's leading early-stage venture firm, headquartered in Seattle and focused on early-stage tech and life sciences companies emerging from regional institutions. WRF Capital shares Madrona's regional concentration and early-stage emphasis, making it a natural operating peer in the same geography.
- Pioneer Square Labs: PSL is a Seattle-based early-stage venture firm that builds technology startups and invests in spinouts from the Pacific Northwest innovation ecosystem. Like WRF Capital, it operates at the earliest stage and closely with regional research institutions, including partnerships at UW.
- The Column Group: The Column Group is an early-stage venture firm that partners with leading academic scientists to found and fund biotech companies. Its model of seeding companies directly out of academic labs makes it a close functional peer to WRF Capital's life sciences investment program at research institutions.
- Atlas Venture: Atlas Venture builds and invests in early-stage biotech companies, often around breakthrough academic science, with a focus on forming new companies. Its emphasis on company formation in therapeutics and platform biology is structurally similar to WRF Capital's spinout-focused life sciences investing.
- Versant Ventures: Versant Ventures is a healthcare-focused venture firm that builds and invests in biotech and medtech companies, often in early-stage syndicates. WRF Capital's biotech and medical device investments at Seattle research institutions overlap meaningfully with Versant's investment categories.
Broad incumbents
- Alexandria Real Estate Equities / Alexandria Venture Investments: Alexandria is a large, established life sciences landlord and venture investor operating broadly across the biotech industry. WRF Capital sits adjacent as a much smaller, regionally focused investor; Alexandria is a broader incumbent for comparison purposes in life sciences venture.
- Y Combinator: Y Combinator is a leading early-stage accelerator that funds and supports startups across industries. While YC is far broader than WRF Capital, both serve as early institutional capital for nascent technology companies and share a program-driven model of providing capital plus operational support at the earliest stages.
Emerging players
- UM Ventures (University of Maryland): UM Ventures is the university-affiliated venture arm that commercializes inventions from University of Maryland research institutions. As a fellow research-institution-affiliated investment vehicle, UM Ventures offers a direct structural analog to WRF Capital's spinout investment model.
Others
- Washington State Department of Commerce (Office of Economic Development): The Washington State Department of Commerce supports innovation ecosystem development through state funding, grants, and ecosystem-building programs in Washington. WRF Capital operates within a broader ecosystem that includes these state-level efforts; the relationship is thematic rather than directly competitive.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights8 records
Customer concentration
WRF Capital social profiles
Digital presenceWRF Capital financial estimates
Financial estimateRevenue estimate
Valuation estimate
WRF Capital leadership team
Management profileNumber of profiles
Profiles12 records
WRF Capital funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WRF Capital M&A and investment
M&A and investmentM&A
Investments36 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WRF Capital
What does WRF Capital do?
WRF Capital is the early-stage venture capital investment vehicle of Washington Research Foundation, investing approximately $5 million annually in Washington state startup companies spun out from nonprofit research institutions. The foundation complements these investments with technology commercialization grants, postdoctoral fellowships, student program funding, and large-scale BioInnovation Grants to bridge the gap between discovery research and commercial investment in life sciences and enabling technologies.
Is WRF Capital a public or private company?
WRF Capital is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was WRF Capital founded?
WRF Capital was founded in 1981. It employs 1 to 10 people.
Where is WRF Capital based?
WRF Capital is headquartered in Seattle, United States, in the North America region.
How does WRF Capital make money?
Two revenue lines are on record. Investment Returns (Portfolio Exit) is the primary driver. The others are licensing Revenue.
Who are WRF Capital's main competitors?
Direct peers on record are ARCH Venture Partners, Madrona Venture Group, Pioneer Square Labs, The Column Group, Atlas Venture and Versant Ventures. Broad incumbents are Alexandria Real Estate Equities / Alexandria Venture Investments and Y Combinator. UM Ventures (University of Maryland) is listed as an emerging player. Washington State Department of Commerce (Office of Economic Development) is listed as an others.
Does WRF Capital have an API?
No public API is recorded for WRF Capital.
What industry is WRF Capital in?
WRF Capital's product category is Venture Capital and Research Foundation Grant Programs. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52394 and its SIC code is 6282.